目的:本研究的目的是研究血清HE4是否与临床风险预后因素和生存结果相关。
方法:在本研究中,2011年1月至2019年10月,72例原发性腹膜癌(PPC)患者参加。初诊时检测血清HE4和CA125水平,手术后,复发前和复发的存在。分析血清HE4水平与临床预后因素的关系,血清HE4水平与总生存期和无复发生存期之间的风险比也通过单变量和多变量生存分析进行了分析.
结果:浆液型HE4和CA125水平显著升高,组织学分级高,晚期和阳性淋巴结状态和残余肿瘤直径超过1厘米,分别,与非浆液型相比,低组织学分级,早期阶段,阴性淋巴结状态和残余肿瘤直径不超过1厘米,分别。HE4是无复发生存率和总生存率的独立预后因素,风险比为5.36(95%置信区间:2.19-13.15)和4.48(95%置信区间:1.87-10.74)。分别。
结论:HE4与PPC患者的临床危险预后因素相关,对PPC患者的复发检测和预后预测有效。
OBJECTIVE: The aim of this study was to investigate whether serum HE4 was associated with clinical risk prognostic factors and survival outcome.
METHODS: In this study, 72 patients with primary peritoneal carcinoma (PPC) from January 2011 to October 2019 participated. Serum HE4 and CA125 levels were detected at primary diagnosis, post-surgery, pre-recurrence and the presence of recurrence. The relations between serum HE4 levels with clinical prognostic factors were analyzed, and the hazard ratios between serum HE4 levels with overall survival and recurrence-free survival were also analyzed by univariate and multivariate survival analysis.
RESULTS: HE4 and CA125 levels were significantly elevated in serous type, high histological grade, advanced stage and positive lymph node status and residual tumor diameter more than 1 cm, respectively, compared with those in non-serous type, low histological grade, early stage, negative lymph node status and residual tumor diameter no more than 1 cm, respectively. HE4 was an independent prognostic factor for recurrence-free survival and overall survival with hazard ratios of 5.36 (95% confidence interval: 2.19-13.15) and 4.48 (95% confidence interval: 1.87-10.74), respectively.
CONCLUSIONS: HE4 is correlated with clinical risk prognostic factors in PPC and is effective in the recurrence detection and predicting outcome in PPC patients.